Navigation Links
Bivalirudin, a new anti-clotting drug may be a safer option for treatment of acute coronary conditions

A novel anti-clotting drug named bivalirudin is turning out to be a better option than combination drug therapy for patients suffering heightened //coronary conditions, for instance heart attacks.

Lead researcher Dr. Gregg W. Stone, a professor of medicine and director of cardiovascular research and education at Columbia University said, "We use it at Columbia in the vast majority of cases. We find that compared to heparin, it is just as effective and safely allows us to do angioplasty with a major reduction in bleeding episodes."

During a study involving 14,000 patients, who had suffered heart attack or other acute coronary syndromes, study participants were administered either a treatment including heparin, or a package including bivalirudin or just bivalirudin.It was found that Bivalrudin reduced the occurrence of artery blockage or severe bleeding by nearly 14 percent compared to the effects of a drug package that included Heparin.

"It makes care of patients in the cath lab much simpler and safer. The big difference was the reduction of major bleeding, almost 50 percent. Major bleeding has been associated with higher mortality, so it is important for the outcome", Dr. Gregg W. Stone said.

Dr. John A. Bittl, an interventional cardiologist at the Munroe Regional Medical Center in Ocala, commented, "This report states that bivalirudin can be used for patents with acute coronary syndrome with a lower risk of bleeding than conventional treatment."

Page: 1

Related medicine news :

1. Enduring anti-clotting treatment avails heart patients
2. Useful device makes spinal surgery safer
3. Transporter offers reliable clues for safer pain medicine
4. Arthritis drugs safer than previously declared
5. Diet and exercise can be a better option to control diabetes
6. Early detection of alcohol abuse is better option for treatment
7. Children obesity has an option in the form of surgery
8. Substituting soymilk for lactose intolerant students n schools: a great option
9. To cope better with HRT, a good option is Hysterectomies
10. Sweet nothings: A fruitful option to assuage the sweet tooth
11. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
Post Your Comments:

(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: